The University of Chicago Header Logo

Connection

Scott Eggener to Lymph Node Excision

This is a "connection" page, showing publications Scott Eggener has written about Lymph Node Excision.
Connection Strength

5.265
  1. National management trends in clinical stage IIA nonseminomatous germ cell tumor (NSGCT) and opportunities to avoid dual therapy. Urol Oncol. 2020 08; 38(8):687.e13-687.e18.
    View in: PubMed
    Score: 0.571
  2. Indications, evolving technique, and early outcomes with robotic retroperitoneal lymph node dissection. Curr Opin Urol. 2018 09; 28(5):461-468.
    View in: PubMed
    Score: 0.510
  3. Clinical and Radiographic Predictors of Great Vessel Resection or Reconstruction During Retroperitoneal Lymph Node Dissection for Testicular Cancer. Urology. 2019 01; 123:186-190.
    View in: PubMed
    Score: 0.510
  4. Risk of lymph node metastases in pathological gleason score=6 prostate adenocarcinoma: Analysis of institutional and population-based databases. Urol Oncol. 2017 01; 35(1):31.e1-31.e6.
    View in: PubMed
    Score: 0.446
  5. Safety and Early Oncologic Effectiveness of Primary Robotic Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Testicular Cancer. Eur Urol. 2017 03; 71(3):476-482.
    View in: PubMed
    Score: 0.436
  6. Critical evaluation of modified templates and current trends in retroperitoneal lymph node dissection. Curr Urol Rep. 2013 Oct; 14(5):511-7.
    View in: PubMed
    Score: 0.363
  7. The role of robot-assisted radical prostatectomy and pelvic lymph node dissection in the management of high-risk prostate cancer: a systematic review. Eur Urol. 2014 May; 65(5):918-27.
    View in: PubMed
    Score: 0.353
  8. The evolution, controversies, and potential pitfalls of modified retroperitoneal lymph node dissection templates. World J Urol. 2009 Aug; 27(4):477-83.
    View in: PubMed
    Score: 0.266
  9. Incidence of disease outside modified retroperitoneal lymph node dissection templates in clinical stage I or IIA nonseminomatous germ cell testicular cancer. J Urol. 2007 Mar; 177(3):937-42; discussion 942-3.
    View in: PubMed
    Score: 0.230
  10. Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors. Cancer. 2007 Feb 01; 109(3):528-35.
    View in: PubMed
    Score: 0.228
  11. Primary retroperitoneal lymph node dissection in clinical stage 2a/b non-seminomatous germ cell tumour. BJU Int. 2025 Apr; 135(4):621-628.
    View in: PubMed
    Score: 0.197
  12. Oncological Outcomes Following Robotic Postchemotherapy Retroperitoneal Lymph Node Dissection for Testicular Cancer: A Worldwide Multicenter Study. Eur Urol Focus. 2025 Mar; 11(2):266-272.
    View in: PubMed
    Score: 0.196
  13. Lymph node count impacts survival following post-chemotherapy retroperitoneal lymphadenectomy for non-seminomatous testicular cancer: a population-based analysis. BJU Int. 2019 11; 124(5):792-800.
    View in: PubMed
    Score: 0.134
  14. International and Multi-institutional Assessment of Factors Associated With Performance and Quality of Lymph Node Dissection During Radical Nephrectomy. Urology. 2019 Jul; 129:132-138.
    View in: PubMed
    Score: 0.133
  15. Management trends for men with early-stage nonseminomatous germ cell tumors of the testicle: An analysis of the National Cancer Database. Cancer. 2017 01 01; 123(2):245-252.
    View in: PubMed
    Score: 0.111
  16. Robotic-assisted pelvic lymph node dissection for prostate cancer: frequency of nodal metastases and oncological outcomes. World J Urol. 2015 Nov; 33(11):1689-94.
    View in: PubMed
    Score: 0.100
  17. The total number of retroperitoneal lymph nodes resected impacts clinical outcome after chemotherapy for metastatic testicular cancer. Urology. 2010 Jun; 75(6):1431-5.
    View in: PubMed
    Score: 0.071
  18. Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection. J Clin Oncol. 2007 Oct 01; 25(28):4365-9.
    View in: PubMed
    Score: 0.060
  19. Accuracy of 18F-Fluorodeoxyglucose Positron Emission Tomography in Early Metastatic Testicular Seminoma: Analysis From the SEMS Trial. J Urol. 2025 Sep; 214(3):272-279.
    View in: PubMed
    Score: 0.050
  20. Contemporary survival results and the role of radiation therapy in patients with node negative seminal vesicle invasion following radical prostatectomy. J Urol. 2005 Apr; 173(4):1150-5.
    View in: PubMed
    Score: 0.050
  21. Risk Factors for Relapse in Nonseminomatous Testicular Cancer After Postchemotherapy Retroperitoneal Lymph Node Dissection With Viable Residual Cancer. J Clin Oncol. 2023 12 01; 41(34):5296-5305.
    View in: PubMed
    Score: 0.045
  22. Surgery in Early Metastatic Seminoma: A Phase II Trial of Retroperitoneal Lymph Node Dissection for Testicular Seminoma With Limited Retroperitoneal Lymphadenopathy. J Clin Oncol. 2023 06 01; 41(16):3009-3018.
    View in: PubMed
    Score: 0.044
  23. Risk of residual cancer after complete response following first-line chemotherapy in men with metastatic non-seminomatous germ cell tumour and International Germ Cell Cancer Cooperative Group intermediate/poor prognosis: A multi-institutional retrospective cohort study. Eur J Cancer. 2023 03; 182:144-154.
    View in: PubMed
    Score: 0.043
  24. Robotic post-chemotherapy retroperitoneal lymph node dissection for testicular cancer: A multicenter collaborative study. Urol Oncol. 2023 02; 41(2):111.e7-111.e14.
    View in: PubMed
    Score: 0.043
  25. Minimally invasive retroperitoneal lymph node dissection for men with testis cancer: a retrospective cohort study of safety and feasibility. World J Urol. 2022 Jun; 40(6):1505-1512.
    View in: PubMed
    Score: 0.041
  26. Recurrence After Robotic Retroperitoneal Lymph Node Dissection Raises More Questions than Answers. Eur Urol. 2019 11; 76(5):610-611.
    View in: PubMed
    Score: 0.034
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.